AbbVie jumps on the BCMA train, opting into TeneoOne buyAfter dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by Share XAbbVie jumps on the BCMA train, opting into TeneoOne buyhttps://pharmaphorum.com/news/abbvie-jumps-on-the-bcma-train-opting-into-teneoone-buy/
ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence dataAstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in Share XASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence datahttps://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/
FDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clashMyovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first Share XFDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clashhttps://pharmaphorum.com/news/fda-clears-myovants-relugolix-for-uterine-fibroids-setting-up-abbvie-clash/
Alvotech files lawsuit challenging AbbVie’s Humira patent thicketBiosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira Share XAlvotech files lawsuit challenging AbbVie’s Humira patent thickethttps://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/
FDA holds back from action over Xeljanz safety studyThe FDA has said it will wait for additional results from last week’s trial showing an increased risk Share XFDA holds back from action over Xeljanz safety studyhttps://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/
Bad news for Pfizer as blockbuster Xeljanz flunks safety studyJAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and Share XBad news for Pfizer as blockbuster Xeljanz flunks safety studyhttps://pharmaphorum.com/news/bad-news-for-pfizer-as-blockbuster-xeljanz-flunks-safety-study/
AZ says Calquence is a safer drug than ImbruvicaAstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment Share XAZ says Calquence is a safer drug than Imbruvicahttps://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
AbbVie scores crucial phase 3 wins with Humira follow-up SkyriziAbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms Share XAbbVie scores crucial phase 3 wins with Humira follow-up Skyrizihttps://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
